TY - JOUR
T1 - Engineered Heart Repair
AU - Fujita, B.
AU - Zimmermann, W. H.
N1 - Funding Information:
B.F. is supported by an Adumed Research stipend. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 13GW0007A (CIRM-ET3)), the German Research Foundation (DFG ZI 708/10-1; SFB 937 TP18, SFB 1002 TPs C04, S1; IRTG 1618 RP12), the European Union FP7 CARE-MI, the Foundation Leducq, and the National Institutes of Health (U01HL099997).
Publisher Copyright:
© 2017 American Society for Clinical Pharmacology and Therapeutics
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).
AB - There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).
UR - http://www.scopus.com/inward/record.url?scp=85021411911&partnerID=8YFLogxK
U2 - 10.1002/cpt.724
DO - 10.1002/cpt.724
M3 - Journal articles
C2 - 28661033
AN - SCOPUS:85021411911
SN - 0009-9236
VL - 102
SP - 197
EP - 199
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 2
ER -
